Zimbabwe

Zimbabwe

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
7.76 (7.45 - 8.04) 2019 Modelled IHME
7.97 (7.70 - 8.23) 2018 Modelled IHME
8.21 (7.93 - 8.48) 2017 Modelled IHME
8.51 (8.23 - 8.76) 2016 Modelled IHME
8.84 (8.52 - 9.11) 2015 Modelled IHME
9.18 (8.86 - 9.46) 2014 Modelled IHME
9.55 (9.23 - 9.86) 2013 Modelled IHME
9.92 (9.58 - 10.23) 2012 Modelled IHME
10.24 (9.89 - 10.59) 2011 Modelled IHME
10.47 (10.10 - 10.83) 2010 Modelled IHME
10.63 (10.27 - 10.98) 2009 Modelled IHME
10.75 (10.39 - 11.07) 2008 Modelled IHME
10.86 (10.50 - 11.19) 2007 Modelled IHME
10.97 (10.61 - 11.29) 2006 Modelled IHME
11.1 (10.69 - 11.43) 2005 Modelled IHME
11.25 (10.87 - 11.57) 2004 Modelled IHME
11.41 (11.02 - 11.72) 2003 Modelled IHME
11.58 (11.17 - 11.90) 2002 Modelled IHME
11.75 (11.34 - 12.12) 2001 Modelled IHME
11.94 (11.52 - 12.33) 2000 Modelled IHME
12.14 (11.72 - 12.55) 1999 Modelled IHME
12.37 (11.95 - 12.78) 1998 Modelled IHME
12.6 (12.16 - 13.03) 1997 Modelled IHME
12.82 (12.34 - 13.27) 1996 Modelled IHME
13.01 (12.50 - 13.50) 1995 Modelled IHME
13.17 (12.65 - 13.64) 1994 Modelled IHME
13.31 (12.80 - 13.80) 1993 Modelled IHME
13.44 (12.91 - 13.94) 1992 Modelled IHME
13.56 (12.96 - 14.09) 1991 Modelled IHME
13.66 (13.03 - 14.20) 1990 Modelled IHME
10.05 (8.14 - 12.30) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
1.77 (1.50 - 2.09) 2019 Modelled IHME
1.82 (1.58 - 2.09) 2018 Modelled IHME
1.84 (1.57 - 2.12) 2017 Modelled IHME
1.82 (1.57 - 2.09) 2016 Modelled IHME
1.8 (1.53 - 2.10) 2015 Modelled IHME
1.82 (1.55 - 2.12) 2014 Modelled IHME
1.87 (1.60 - 2.16) 2013 Modelled IHME
1.95 (1.66 - 2.25) 2012 Modelled IHME
2.05 (1.74 - 2.40) 2011 Modelled IHME
2.17 (1.82 - 2.56) 2010 Modelled IHME
2.34 (1.98 - 2.74) 2009 Modelled IHME
2.59 (2.20 - 3.01) 2008 Modelled IHME
2.89 (2.44 - 3.34) 2007 Modelled IHME
3.22 (2.70 - 3.72) 2006 Modelled IHME
3.52 (2.95 - 4.10) 2005 Modelled IHME
3.79 (3.22 - 4.38) 2004 Modelled IHME
4.05 (3.45 - 4.65) 2003 Modelled IHME
4.33 (3.70 - 5.01) 2002 Modelled IHME
4.65 (3.96 - 5.38) 2001 Modelled IHME
5.04 (4.28 - 5.91) 2000 Modelled IHME
5.7 (4.90 - 6.59) 1999 Modelled IHME
6.65 (5.74 - 7.61) 1998 Modelled IHME
7.67 (6.62 - 8.71) 1997 Modelled IHME
8.54 (7.37 - 9.69) 1996 Modelled IHME
9.04 (7.72 - 10.33) 1995 Modelled IHME
9.26 (7.97 - 10.65) 1994 Modelled IHME
9.45 (8.07 - 10.91) 1993 Modelled IHME
9.6 (8.19 - 11.12) 1992 Modelled IHME
9.7 (8.27 - 11.29) 1991 Modelled IHME
9.73 (8.23 - 11.47) 1990 Modelled IHME
4.38 (2.92 - 6.33) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
37 (28 - 47) 2019 Modelled IHME
37 (28 - 47) 2018 Modelled IHME
37 (29 - 47) 2017 Modelled IHME
38 (29 - 47) 2016 Modelled IHME
38 (29 - 47) 2015 Modelled IHME
38 (29 - 47) 2014 Modelled IHME
38 (29 - 47) 2013 Modelled IHME
38 (29 - 47) 2012 Modelled IHME
38 (30 - 47) 2011 Modelled IHME
38 (30 - 47) 2010 Modelled IHME
38 (30 - 47) 2009 Modelled IHME
39 (31 - 48) 2008 Modelled IHME
39 (32 - 48) 2007 Modelled IHME
40 (32 - 49) 2006 Modelled IHME
41 (33 - 49) 2005 Modelled IHME
41 (34 - 50) 2004 Modelled IHME
42 (34 - 51) 2003 Modelled IHME
42 (35 - 51) 2002 Modelled IHME
43 (35 - 52) 2001 Modelled IHME
43 (35 - 52) 2000 Modelled IHME
43 (35 - 53) 1999 Modelled IHME
44 (36 - 53) 1998 Modelled IHME
44 (36 - 54) 1997 Modelled IHME
44 (36 - 54) 1996 Modelled IHME
44 (36 - 54) 1995 Modelled IHME
44 (36 - 53) 1994 Modelled IHME
43 (35 - 52) 1993 Modelled IHME
43 (34 - 52) 1992 Modelled IHME
42 (34 - 51) 1991 Modelled IHME
42 (33 - 51) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
89 2018 Survey/reported WHO/UNICEF
89 2017 Survey/reported WHO/UNICEF
90 2016 Survey/reported WHO/UNICEF
87 2015 Survey/reported WHO/UNICEF
91 2014 Survey/reported WHO/UNICEF
95 2013 Survey/reported WHO/UNICEF
97 2012 Survey/reported WHO/UNICEF
94 2011 Survey/reported WHO/UNICEF
90 2010 Survey/reported WHO/UNICEF
73 2009 Survey/reported WHO/UNICEF
75 2008 Survey/reported WHO/UNICEF
72 2007 Survey/reported WHO/UNICEF
68 2006 Survey/reported WHO/UNICEF
65 2005 Survey/reported WHO/UNICEF
68 2004 Survey/reported WHO/UNICEF
70 2003 Survey/reported WHO/UNICEF
73 2002 Survey/reported WHO/UNICEF
76 2001 Survey/reported WHO/UNICEF
79 2000 Survey/reported WHO/UNICEF
31 1999 Survey/reported WHO/UNICEF
24 1998 Survey/reported WHO/UNICEF
16 1997 Survey/reported WHO/UNICEF
9 1996 Survey/reported WHO/UNICEF
1 1995 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
0 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV elimination goal
HBV National Action Plan
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Few (1-10%)
% of substance use disorder facilities offering hepatitis treatment
Few (1-10%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
1.63 (1.31 - 2.05) 2019 Modelled IHME
1.64 (1.31 - 2.05) 2018 Modelled IHME
1.64 (1.32 - 2.06) 2017 Modelled IHME
1.63 (1.30 - 2.02) 2016 Modelled IHME
1.61 (1.30 - 2.01) 2015 Modelled IHME
1.61 (1.29 - 2) 2014 Modelled IHME
1.62 (1.30 - 2.01) 2013 Modelled IHME
1.62 (1.30 - 2.01) 2012 Modelled IHME
1.62 (1.30 - 2.02) 2011 Modelled IHME
1.62 (1.30 - 2.03) 2010 Modelled IHME
1.61 (1.29 - 2.02) 2009 Modelled IHME
1.6 (1.29 - 2) 2008 Modelled IHME
1.58 (1.27 - 1.97) 2007 Modelled IHME
1.57 (1.25 - 1.95) 2006 Modelled IHME
1.55 (1.23 - 1.93) 2005 Modelled IHME
1.53 (1.22 - 1.91) 2004 Modelled IHME
1.51 (1.21 - 1.88) 2003 Modelled IHME
1.48 (1.19 - 1.85) 2002 Modelled IHME
1.46 (1.17 - 1.81) 2001 Modelled IHME
1.44 (1.16 - 1.80) 2000 Modelled IHME
1.43 (1.15 - 1.80) 1999 Modelled IHME
1.42 (1.14 - 1.79) 1998 Modelled IHME
1.41 (1.14 - 1.78) 1997 Modelled IHME
1.41 (1.13 - 1.78) 1996 Modelled IHME
1.41 (1.13 - 1.78) 1995 Modelled IHME
1.41 (1.13 - 1.76) 1994 Modelled IHME
1.41 (1.13 - 1.75) 1993 Modelled IHME
1.41 (1.12 - 1.75) 1992 Modelled IHME
1.41 (1.13 - 1.75) 1991 Modelled IHME
1.41 (1.13 - 1.75) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
1.6 (1 - 9.10) 2014 Modelled Gower et al, 2014

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
33 (24 - 42) 2019 Modelled IHME
33 (23 - 42) 2018 Modelled IHME
32 (23 - 42) 2017 Modelled IHME
32 (24 - 42) 2016 Modelled IHME
33 (24 - 42) 2015 Modelled IHME
33 (23 - 42) 2014 Modelled IHME
32 (24 - 41) 2013 Modelled IHME
32 (24 - 41) 2012 Modelled IHME
32 (24 - 41) 2011 Modelled IHME
32 (24 - 41) 2010 Modelled IHME
32 (24 - 40) 2009 Modelled IHME
31 (23 - 39) 2008 Modelled IHME
30 (23 - 38) 2007 Modelled IHME
30 (22 - 38) 2006 Modelled IHME
29 (22 - 37) 2005 Modelled IHME
29 (22 - 36) 2004 Modelled IHME
28 (21 - 36) 2003 Modelled IHME
27 (20 - 35) 2002 Modelled IHME
27 (20 - 35) 2001 Modelled IHME
27 (20 - 35) 2000 Modelled IHME
26 (19 - 34) 1999 Modelled IHME
26 (18 - 33) 1998 Modelled IHME
25 (18 - 33) 1997 Modelled IHME
25 (18 - 33) 1996 Modelled IHME
26 (18 - 33) 1995 Modelled IHME
26 (19 - 33) 1994 Modelled IHME
27 (19 - 35) 1993 Modelled IHME
27 (20 - 36) 1992 Modelled IHME
28 (20 - 36) 1991 Modelled IHME
29 (20 - 38) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV elimination goal
HBV National Action Plan
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Few (1-10%)
% of substance use disorder facilities offering hepatitis treatment
Few (1-10%)

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
7.76 (%)
2019
(7.45 - 8.04(%))
IHME
HCV (RNA/cAg+)
1.63 (%)
2019
(1.31 - 2.05(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
861
2019
(592 - 1,197)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
964
2019
(654 - 1,346)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
1.77 (%)
2019, latest modelled
(1.50 - 2.09(%))
IHME

Prevalence PWID

No data available

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

HCV
0
2016
(0 - 0)
Harm Reduction International, 2016
Eligible for HBV generic medicines
Eligible for HCV generic medicines